Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization-Reference-Cited by-同舟云学术

Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization

Published:2019-08-22 Issue:12 Volume:35 Page:2159-2168
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

El Khoury Antoine¹,Patel Charmi¹,Huang Ahong²,Wang Li²,Bashyal Richa²

Affiliation:

1. Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

2. STATinMED Research, Plano, TX, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1651129

Reference39 articles.

1. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics

2. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010

3. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans

4. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate

5. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review;BMC Psychiatry;2024-01-19

2. A systematic review of approaches to improve medication adherence in homeless adults with psychiatric disorders;Frontiers in Psychiatry;2024-01-08

3. Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis;CNS Drugs;2023-07-25

4. Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs;Neuropsychiatric Disease and Treatment;2023-03

5. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies;Schizophrenia;2023-02-11